Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093Phase 3Recruiting
- Sponsor
- Nurix Therapeutics
- Start
- Aug 2026
- Primary completion
- Oct 2029
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 3 trial of bexobrutideg in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Nurix Therapeutics. Started Aug 2026; status: recruiting.
02
Drugs
bexobrutideg
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07516093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07516093.